MRC Holland is a company based out of The Netherlands which has a proprietary technology - MLPA (Multiplex Ligation-dependant Probe Amplification (MLPA), a multiplex PCR method which enables detection of variation in copy number (CNV) of up to 60 DNA sequences in one reaction and can handle up to 96 DNA samples at a stretch with results being available within 24 hours.
Introduced in 2002, MLPA is a gold standard in CNV detection and has proven to be a robust and easy-to-use techniques, and since it is highly sensitive to even a single nucleotide difference, it has applications in detection of point mutations.
MLPA, when used in combination with a methylation-sensitive restriction enzyme, can be applied to detect DNA methylation patterns (MS_MLPA). The first Melt Assay for spinal muscular atrophy (SMA) newborn screening was launched in 2018 and the first digitalMLPA technique based assay was launched in 2020. digitalMLPA combines the trusted quality of MLPA with the power of next-generation sequencing to examine many more target sequences in a single reaction.
In diagnostics and research of both human genetic disorders and tumors, MLPA is used in laboratories worldwide.